Open AccessACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation
Author(s) -
Tarek Alhamad,
John Manllo Dieck,
Usman Younus,
Dany Matar,
Sami Alasfar,
Vikas Vujjini,
D. Wall,
Bilal Kanawati,
Jochen Reiser,
Daniel C. Brennan,
Nada Alachkar
Publication year - 2019
Publication title -
transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002320
Subject(s) - medicine , rituximab , focal segmental glomerulosclerosis , interquartile range , transplantation , kidney transplantation , urology , creatinine , proteinuria , gastroenterology , kidney , immunosuppression , surgery , lymphoma
Treatment of focal segmental glomerular sclerosis (FSGS) after kidney transplantation is challenging with unpredictable outcomes. The objective was to investigate the use of adrenocorticotropic hormone (ACTH) analogue gel in kidney transplant recipients with de novo or recurrent FSGS resistant to therapeutic plasma exchange (TPE) and/or rituximab.